FDA Accepts Aveo Kidney Cancer Pill Application
Aveo Oncology announces that the Food and Drug Administration will complete a review of its cancer pill Tivopath by July 28.
Aveo and its partner Astellas Pharma Inc. want to market Tivopath as a treatment for advanced kidney cancer. The companies said the FDA accepted their application, and the agency will conduct a standard 10-month review. Astellas will pay Aveo $15 million now that the filing has been accepted.
Tivopath, or tivozanib, is a tablet intended to be taken once per day. The companies are also studying the drug as a treatment for other solid tumors, including cancers of the breast and colon.
Release Date: Nov. 27, 2012
Source: The Associated Press